Skip to content
EntityQ5280143· pop 7· linked from 191 articles

diquafosol

Sign in to save

Also known as INS-365, INS365, P1,P4-Bis(5'-uridyl) tetrahydrogen tetraphosphate, UppppU

Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010. It is formulated as a 3% ophthalmic solution of the tetrasodium salt.

~1 min read

Encyclopedic overview

1 sections
Contents
  • References

{{Chembox | ImageFile = Diquafosol.svg | ImageClass = skin-invert-image | ImageSize = 250px | IUPACName = O1,O7-Di(5′-deoxyuridin-5′-yl) tetrahydrogen tetraphosphate | SystematicName = O1,O7-Bis{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxyoxolan-2-yl]methyl} tetrahydrogen tetraphosphate | OtherNames = P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium |Section1= |Section2= |Section3= |Section5= | Section6 = }}

Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010. It is formulated as a 3% ophthalmic solution of the tetrasodium salt.

Excerpted from Wikipedia’s “diquafosol” article, available under the CC BY-SA 4.0 licence.

Available in 7 languages

via Wikidata sitelinks · CC0